Answers are grounded in this paper and cite their sources.
BACKGROUND: Endemic mycoses, caused by Blastomyces, Coccidioides, Emergomyces, Histoplasma, Paracoccidioides, Sporothrix, and Talaromyces marneffei, represent an important global health challenge. Expanding endemic regions, climatic change, improved diagnostics, increased disease awareness, and an increasing at-risk population have contributed to rising case numbers. These infections affect both immunocompetent and immunocompromised hosts and exhibit marked clinical heterogeneity. Current treatment response guidance, established by the Mycoses Study Group and the European Organization for Research and Treatment of Cancer in 2008, are primarily tailored for invasive yeast and mold infections and are inadequate for endemic mycoses due to their complexity and heterogeneity. METHODS: An international, multidisciplinary expert panel convened through the Mycoses Study Group Education and Research Consortium and the European Confederation of Medical Mycology to develop consensus guidance for treatment response assessment in endemic mycoses. The process included a structured literature review, expert discussion, regulatory consultation, patient input, and public comment, culminating in consensus-based response criteria. RESULTS: The proposed guidance response criteria encompass clinical, mycologic, and radiologic assessments. CONCLUSIONS: The new criteria aim to improve the accuracy and standardize the assessment of treatment response, enabling comparison and pooling results across clinical trials while addressing the unique challenges posed by these diverse pathogens.
No takes yet. Share an insight, caveat, or question.
Thompson et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: